A multicenter prospective real world study of neoadjuvant chemotherapy efficacy prediction for gastric cancer based on artificial intelligence

Not Applicable

Completed

• Conditions: Gastric cancer

• Registration Number: ChiCTR2300068917
• Lead Sponsor: China Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1.Patient has given informed consent;<br>2.Aged >= 18 years;<br>3.Patient has been diagnosed with gastric adenocarcinoma through histopathological biopsy and has available pathological WSI (Whole Slide Imaging);<br>4.Underwent standardized contrast-enhanced abdominal CT scan prior to neoadjuvant chemotherapy;<br>5.Diagnosed with locally advanced gastric cancer through contrast-enhanced abdominal CT scan, with infiltration beyond the submucosa and no distant metastasis;<br>6.No previous gastric surgery;<br>7.No history of other malignancies before neoadjuvant treatment;<br>8.No anti-tumor treatment before the contrast-enhanced abdominal CT scan;<br>9.No mental disorders or cognitive impairment.

Exclusion Criteria

1.Receiving neoadjuvant chemotherapy regimens other than XELOX and SOX;<br>2.Did not undergo radical surgery after neoadjuvant chemotherapy;<br>3.Postoperative pathological TRG (Tumor Regression Grade) is unknown;<br>4.Poor quality of CT images (due to insufficient gastric filling or artifacts) or poor quality of WSI (Whole Slide Imaging);<br>5.Perioperative death.

Study & Design

• Study Type: Observational study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Tumor regression grade;Efficacy evaluation criteria for solid tumors (RECIST 1.1);

Secondary Outcome Measures

Name	Time	Method
overall survival;event-free survival;